Elderly patients with metastatic neuroendocrine tumors are undertreated and have shorter survival: The LyREMeNET study

Elderly patients with metastatic neuroendocrine tumors are undertreated and have shorter survival: The LyREMeNET study: Introduction: The incidence of neuroendocrine tumors (NETs) is rising, especially in elderly patients. The elderly cancer population present considerable challenges, yet little is known about the characteristics, treatment pattern, and outcomes of metastatic NET patients. Methods: The Lyon Real-life Evidence in Metastatic NeuroEndocrine Tumors study (LyREMeNET, NCT03863106) included consecutive metastatic NET patients (mNETs), diagnosed between January 1990 and December 2017. The exclusion criteria were non-metastatic NET, poorly differentiated neuroendocrine carcinoma, and mixed neuroendocrine-nonneuroendocrine neoplasms. We aim to compare patients ≥70 years old (yo) to patients